CEL-SCI Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CVM research report →
About the company
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology.
- CEO
- Geert R. Kersten
- IPO
- 1983
- Employees
- 43
- HQ
- Vienna, VA, US
Price Chart
- Market Cap
- $7.83M
- P/E
- -0.33
- P/S
- 0.00
- P/B
- 1.35
- EV/EBITDA
- -0.79
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -221.50%
- ROIC
- -143.23%
- Revenue
- $0 · 0.00%
- Net Income
- $-25,411,055 · 5.61%
- EPS
- $-6.27 · 53.56%
- Op Income
- $-24,809,736
- FCF YoY
- -90653.05%
- 52W High
- $13.48
- 52W Low
- $0.89
- 50D MA
- $1.59
- 200D MA
- $4.95
- Beta
- 0.60
- Avg Volume
- 465.38K
Get TickerSpark's AI analysis on CVM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | TALOR EYAL | other | 2,307 |
| Jun 30, 26 | PRICHEP PATRICIA B | other | 4,125 |
| Jun 30, 26 | KERSTEN GEERT R | other | 5,192 |
| May 14, 26 | KERSTEN GEERT R | buy | 300,000 |
| May 13, 26 | KERSTEN GEERT R | buy | 100,000 |
| Mar 31, 26 | TALOR EYAL | other | 747 |
| Mar 31, 26 | PRICHEP PATRICIA B | other | 1,336 |
| Mar 31, 26 | KERSTEN GEERT R | other | 1,682 |
| Jan 22, 26 | KERSTEN GEERT R | buy | 38,023 |
| Dec 31, 25 | TALOR EYAL | other | 456 |
Our CVM coverage
Recent articles, reports, and earnings notes.
No research on CVM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CVM report →Similar companies
Peers in the same neighborhood.